Editorial
Peptide research blog.
Evidence-based articles, stacking guides, industry news, and research deep dives — published weekly.
Eli Lilly Sued 6 Retatrutide Vendors (Here's What To Know)
On August 12, 2026, Eli Lilly sued six US companies selling retatrutide — a med spa, a compounding pharmacy, and four peptide sellers. We read the complaints: Lilly built its case partly out of Reddit posts. Here's who was named, what it means if you've been buying, and what it doesn't change.
GLP-1 Maintenance Dose: What Lowering to 5 mg Costs You
For years the honest answer to "do I have to stay on this forever?" was that nobody had tested lowering the dose. Somebody has now. SURMOUNT-MAINTAIN randomly assigned 378 people to hold their top tirzepatide dose, drop to 5 mg, or stop — then followed them for another full year. Lowering works far better than quitting. It is not free. Here is what it costs, measured from both of the two zeros that matter.
Does BPC-157 Actually Heal Injuries? The Evidence
BPC-157 is the go-to "healing peptide" for tendon, muscle, and joint injuries — but does it actually work? We grade the animal vs human evidence, cover the first randomized human trial now recruiting, and set realistic expectations for recovery.
Retatrutide's Biologic Path: What It Means for You
Eli Lilly just posted two more Phase 3 wins for retatrutide and says it will file with the FDA in early 2027 — as a biologic. That single word is the outcome of a legal fight Lilly itself started over a one-amino-acid technicality, and it decides whether cheaper compounded copies can ever legally exist. Here's the honest breakdown for anyone eyeing today's grey market.
FDA Peptide Vote: 6 of 7 Cleared, DSIP Rejected
Over two days, an FDA committee recommended six of seven peptides for legal compounding, overruling the agency's own scientists every time — and rejected one, emideltide (DSIP), by a single vote. The twist: DSIP had the most human trial evidence in the room, and the people who use it agree with the panel. Here is the complete two-day record: why emideltide failed, the indications FDA actually reviewed (far narrower than you think), and an honest answer to when any of this becomes legal.
Peptide Side Effects: A Complete Safety Guide by Compound
Every peptide carries a unique side effect profile. This guide organizes adverse effects by compound category and includes a master reference table covering 20+ peptides.
Are Peptides Safe? What 50+ Clinical Studies Actually Show
Are peptides safe? The answer depends on the compound, the source, and the user. This article reviews 50+ clinical studies to separate evidence from hype across every major peptide category.
Bacteriostatic Water vs Sterile Water for Peptides
Choosing the wrong diluent can destroy your peptide or create a contamination risk. This guide explains the critical differences between bacteriostatic water and sterile water and when to use each.
Peptide Compounding Pharmacy Ban: What It Means
FDA enforcement against peptide compounding pharmacies intensified in 2025-2026. This article explains what happened, which compounds are affected, and what options remain for consumers.
FDA Peptide Regulations 2026: What Changed and What's Coming
The FDA's peptide regulatory landscape shifted dramatically in 2025-2026. From the compounding crackdown to new bulk drug substance categories, here is what changed and what comes next.
Compounded Semaglutide vs Brand Name: Is It Safe? (2026)
Compounded semaglutide surged in popularity during the Ozempic shortage. With supply stabilizing and FDA scrutiny increasing, here is what you need to know about compounded vs brand-name GLP-1 medications in 2026.
Retatrutide Phase 3 Results: What We Know So Far (2026)
Retatrutide is the first GLP-1/GIP/glucagon triple agonist in late-stage clinical trials. Phase 2 data showed unprecedented weight loss. Here is what we know about the phase 3 program and what to expect next.
Oral Wegovy Is Here: What Oral GLP-1s Mean in 2026
The FDA approved oral Wegovy in December 2025 (launched January 2026), making injectable-free GLP-1 therapy a reality. Here is everything the research says about oral semaglutide and what comes next.
Peptides vs SARMs vs Steroids: Understanding the Differences
Many newcomers confuse peptides with SARMs and steroids. This guide breaks down the fundamental differences in how they work, their legal status, and their safety profiles.